Coagulation defects, purpura and other hemorrhagic conditions (D65-D69)
D65Disseminated intravascular coagulation [defibrination syndrome]
› Afibrinogenemia, acquired
› Consumption coagulopathy
› COVID-19 associated diffuse or disseminated intravascular coagulopathy
› Diffuse or disseminated intravascular coagulation [DIC]
› Fibrinolytic hemorrhage, acquired
› Fibrinolytic purpura
› Purpura fulminans
Code Also: , if applicable, associated condition
Excludes 1: disseminated intravascular coagulation (complicating):
› abortion or ectopic or molar pregnancy (O00-O07, O08.1)
› in newborn (P60)
› pregnancy, childbirth and the puerperium (O45.0, O46.0, O67.0, O72.3)
D66Hereditary factor VIII deficiency
› Classical hemophilia
› Deficiency factor VIII (with functional defect)
› Hemophilia NOS
› Hemophilia A
Excludes 1: factor VIII deficiency with vascular defect (D68.0-)
D67Hereditary factor IX deficiency
› Christmas disease
› Factor IX deficiency (with functional defect)
› Hemophilia B
› Plasma thromboplastin component [PTC] deficiency
D68Other coagulation defects
Excludes 1: abnormal coagulation profile NOS (R79.1)
Excludes 2: coagulation defects complicating abortion or ectopic or molar pregnancy (O00-O07, O08.1)
› coagulation defects complicating pregnancy, childbirth and the puerperium (O45.0, O46.0, O67.0, O72.3)
D68.0Von Willebrand disease
Excludes 1: capillary fragility (hereditary) (D69.8)
› factor VIII deficiency NOS (D66)
› factor VIII deficiency with functional defect (D66)
D68.00Von Willebrand disease, unspecified
D68.01Von Willebrand disease, type 1
› Partial quantitative deficiency of von Willebrand factor
› Type 1C von Willebrand disease
D68.02Von Willebrand disease, type 2
› Qualitative defects of von Willebrand factor
D68.020Von Willebrand disease, type 2A
› Qualitative defects of von Willebrand factor with decreased platelet adhesion and selective deficiency of high-molecular-weight multimers
D68.021Von Willebrand disease, type 2B
› Qualitative defects of von Willebrand factor with high-molecular-weight von Willebrand factor loss
› Qualitative defects of von Willebrand factor with hyper-adhesive forms
› Qualitative defects of von Willebrand factor with increased affinity for platelet glycoprotein lb
D68.022Von Willebrand disease, type 2M
› Qualitative defects of von Willebrand factor with defective platelet adhesion with a normal size distribution of von Willebrand factor multimers
D68.023Von Willebrand disease, type 2N
› Qualitative defects of von Willebrand factor with defective von Willebrand factor to factor VIII binding
› Qualitative defects of von Willebrand factor with markedly decreased affinity for factor VIII
D68.029Von Willebrand disease, type 2, unspecified
› Qualitative defect in von Willebrand factor function, with no further subtyping
D68.03Von Willebrand disease, type 3
› (Near) complete absence of von Willebrand factor
› Total quantitative deficiency of von Willebrand factor
D68.04Acquired von Willebrand disease
› Acquired von Willebrand syndrome
D68.09Other von Willebrand disease
› Platelet-type von Willebrand disease
› Pseudo-von Willebrand disease
Code Also: , if applicable, qualitative platelet defects (D69.1)
D68.1Hereditary factor XI deficiency
› Hemophilia C
› Plasma thromboplastin antecedent [PTA] deficiency
› Rosenthal's disease
D68.2Hereditary deficiency of other clotting factors
› AC globulin deficiency
› Congenital afibrinogenemia
› Deficiency of factor I [fibrinogen]
› Deficiency of factor II [prothrombin]
› Deficiency of factor V [labile]
› Deficiency of factor VII [stable]
› Deficiency of factor X [Stuart-Prower]
› Deficiency of factor XII [Hageman]
› Deficiency of factor XIII [fibrin stabilizing]
› Dysfibrinogenemia (congenital)
› Hypoproconvertinemia
› Owren's disease
› Proaccelerin deficiency
D68.3Hemorrhagic disorder due to circulating anticoagulants
D68.31Hemorrhagic disorder due to intrinsic circulating anticoagulants, antibodies, or inhibitors
D68.311Acquired hemophilia
› Autoimmune hemophilia
› Autoimmune inhibitors to clotting factors
› Secondary hemophilia
D68.312Antiphospholipid antibody with hemorrhagic disorder
› Lupus anticoagulant (LAC) with hemorrhagic disorder
› Systemic lupus erythematosus [SLE] inhibitor with hemorrhagic disorder
Excludes 1: antiphospholipid antibody, finding without diagnosis (R76.0)
› antiphospholipid antibody syndrome (D68.61)
› antiphospholipid antibody with hypercoagulable state (D68.61)
› lupus anticoagulant (LAC) finding without diagnosis (R76.0)
› lupus anticoagulant (LAC) with hypercoagulable state (D68.62)
› systemic lupus erythematosus [SLE] inhibitor finding without diagnosis (R76.0)
› systemic lupus erythematosus [SLE] inhibitor with hypercoagulable state (D68.62)
D68.318Other hemorrhagic disorder due to intrinsic circulating anticoagulants, antibodies, or inhibitors
› Antithromboplastinemia
› Antithromboplastinogenemia
› Hemorrhagic disorder due to intrinsic increase in antithrombin
› Hemorrhagic disorder due to intrinsic increase in anti-VIIIa
› Hemorrhagic disorder due to intrinsic increase in anti-IXa
› Hemorrhagic disorder due to intrinsic increase in anti-XIa
D68.32Hemorrhagic disorder due to extrinsic circulating anticoagulants
› Drug-induced hemorrhagic disorder
› Hemorrhagic disorder due to increase in anti-IIa
› Hemorrhagic disorder due to increase in anti-Xa
› Hyperheparinemia
Use Additional Code: code for adverse effect, if applicable, to identify drug (T45.515, T45.525)
D68.4Acquired coagulation factor deficiency
› Deficiency of coagulation factor due to liver disease
› Deficiency of coagulation factor due to vitamin K deficiency
Excludes 1: vitamin K deficiency of newborn (P53)
D68.5Primary thrombophilia
› Primary hypercoagulable states
Excludes 1: antiphospholipid syndrome (D68.61)
› lupus anticoagulant (D68.62)
› secondary activated protein C resistance (D68.69)
› secondary antiphospholipid antibody syndrome (D68.69)
› secondary lupus anticoagulant with hypercoagulable state (D68.69)
› secondary systemic lupus erythematosus [SLE] inhibitor with hypercoagulable state (D68.69)
› systemic lupus erythematosus [SLE] inhibitor finding without diagnosis (R76.0)
› systemic lupus erythematosus [SLE] inhibitor with hemorrhagic disorder (D68.312)
› thrombotic thrombocytopenic purpura (M31.19)
D68.51Activated protein C resistance
› Factor V Leiden mutation
D68.52Prothrombin gene mutation
D68.59Other primary thrombophilia
› Antithrombin III deficiency
› Hypercoagulable state NOS
› Primary hypercoagulable state NEC
› Primary thrombophilia NEC
› Protein C deficiency
› Protein S deficiency
› Thrombophilia NOS
D68.6Other thrombophilia
› Other hypercoagulable states
Excludes 1: diffuse or disseminated intravascular coagulation [DIC] (D65)
› heparin induced thrombocytopenia (HIT) (D75.82-)
› hyperhomocysteinemia (E72.11)
D68.61Antiphospholipid syndrome
› Anticardiolipin syndrome
› Antiphospholipid antibody syndrome
Excludes 1: anti-phospholipid antibody, finding without diagnosis (R76.0)
› anti-phospholipid antibody with hemorrhagic disorder (D68.312)
› lupus anticoagulant syndrome (D68.62)
D68.62Lupus anticoagulant syndrome
› Lupus anticoagulant
› Presence of systemic lupus erythematosus [SLE] inhibitor
Excludes 1: anticardiolipin syndrome (D68.61)
› antiphospholipid syndrome (D68.61)
› lupus anticoagulant (LAC) finding without diagnosis (R76.0)
› lupus anticoagulant (LAC) with hemorrhagic disorder (D68.312)
D68.69Other thrombophilia
› COVID-19 associated hypercoagulability
› Hypercoagulable states NEC
› Secondary hypercoagulable state NOS
Code Also: , if applicable, associated condition
D68.8Other specified coagulation defects
› COVID-19 associated coagulopathy
Code Also: , if applicable, associated condition
Excludes 1: hemorrhagic disease of newborn (P53)
D68.9Coagulation defect, unspecified
D69Purpura and other hemorrhagic conditions
Excludes 1: benign hypergammaglobulinemic purpura (D89.0)
› cryoglobulinemic purpura (D89.1)
› essential (hemorrhagic) thrombocythemia (D47.3)
› hemorrhagic thrombocythemia (D47.3)
› purpura fulminans (D65)
› thrombotic thrombocytopenic purpura (M31.19)
› Waldenström hypergammaglobulinemic purpura (D89.0)
D69.0Allergic purpura
› Allergic vasculitis
› Nonthrombocytopenic hemorrhagic purpura
› Nonthrombocytopenic idiopathic purpura
› Purpura anaphylactoid
› Purpura Henoch(-Schönlein)
› Purpura rheumatica
› Vascular purpura
Excludes 1: thrombocytopenic hemorrhagic purpura (D69.3)
D69.1Qualitative platelet defects
› Bernard-Soulier [giant platelet] syndrome
› Glanzmann's disease
› Grey platelet syndrome
› Thromboasthenia (hemorrhagic) (hereditary)
› Thrombocytopathy
Excludes 1: hemolytic-uremic syndrome (D59.3-)
Excludes 2: von Willebrand disease (D68.0-)
D69.2Other nonthrombocytopenic purpura
› Purpura NOS
› Purpura simplex
› Senile purpura
D69.3Immune thrombocytopenic purpura
› Hemorrhagic (thrombocytopenic) purpura
› Idiopathic thrombocytopenic purpura
› Tidal platelet dysgenesis
D69.4Other primary thrombocytopenia
Excludes 1: transient neonatal thrombocytopenia (P61.0)
› Wiskott-Aldrich syndrome (D82.0)
D69.41Evans syndrome
D69.42Congenital and hereditary thrombocytopenia purpura
› Congenital thrombocytopenia
› Hereditary thrombocytopenia
Code First: congential or hereditary disorder, such as:
› thrombocytopenia with absent radius (TAR syndrome) (Q87.2)
D69.49Other primary thrombocytopenia
› Megakaryocytic hypoplasia
› Primary thrombocytopenia NOS
D69.5Secondary thrombocytopenia
Excludes 1: heparin induced thrombocytopenia (HIT) (D75.82-)
› transient thrombocytopenia of newborn (P61.0)
D69.51Posttransfusion purpura
› Posttransfusion purpura from whole blood (fresh) or blood products
› PTP
D69.59Other secondary thrombocytopenia
D69.6Thrombocytopenia, unspecified
D69.8Other specified hemorrhagic conditions
› Capillary fragility (hereditary)
› Vascular pseudohemophilia
D69.9Hemorrhagic condition, unspecified